| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papillomavirus Infections | 36 | 2023 | 239 | 8.260 |
Why?
|
| Uterine Cervical Neoplasms | 37 | 2023 | 275 | 7.790 |
Why?
|
| Early Detection of Cancer | 56 | 2023 | 395 | 7.780 |
Why?
|
| Papillomavirus Vaccines | 22 | 2022 | 58 | 7.280 |
Why?
|
| Carcinoma, Hepatocellular | 19 | 2023 | 386 | 3.360 |
Why?
|
| Liver Neoplasms | 19 | 2023 | 737 | 2.900 |
Why?
|
| Mammography | 15 | 2021 | 463 | 2.680 |
Why?
|
| Vaccination | 12 | 2022 | 256 | 2.450 |
Why?
|
| Safety-net Providers | 10 | 2019 | 37 | 2.410 |
Why?
|
| Patient Acceptance of Health Care | 14 | 2022 | 238 | 2.320 |
Why?
|
| Parents | 9 | 2023 | 272 | 2.280 |
Why?
|
| Breast Neoplasms | 24 | 2021 | 2904 | 2.260 |
Why?
|
| Health Behavior | 11 | 2023 | 182 | 2.200 |
Why?
|
| Mass Screening | 30 | 2022 | 601 | 2.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 15 | 2021 | 500 | 2.050 |
Why?
|
| Alphapapillomavirus | 8 | 2022 | 45 | 1.950 |
Why?
|
| Colorectal Neoplasms | 18 | 2022 | 937 | 1.920 |
Why?
|
| Liver Cirrhosis | 16 | 2023 | 299 | 1.790 |
Why?
|
| Population Surveillance | 8 | 2018 | 214 | 1.670 |
Why?
|
| Surveys and Questionnaires | 18 | 2023 | 2500 | 1.650 |
Why?
|
| Texas | 23 | 2023 | 101 | 1.570 |
Why?
|
| Middle Aged | 83 | 2023 | 24740 | 1.540 |
Why?
|
| Female | 116 | 2023 | 44216 | 1.530 |
Why?
|
| Delivery of Health Care | 10 | 2023 | 422 | 1.490 |
Why?
|
| Adult | 70 | 2023 | 25518 | 1.380 |
Why?
|
| Humans | 145 | 2023 | 85777 | 1.340 |
Why?
|
| Neoplasms | 11 | 2023 | 2895 | 1.300 |
Why?
|
| Papanicolaou Test | 10 | 2022 | 38 | 1.280 |
Why?
|
| Vaginal Smears | 13 | 2023 | 68 | 1.240 |
Why?
|
| Adolescent | 34 | 2023 | 8959 | 1.210 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2023 | 578 | 1.160 |
Why?
|
| Language | 5 | 2019 | 151 | 1.150 |
Why?
|
| Aged | 53 | 2023 | 18161 | 1.150 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2023 | 118 | 1.120 |
Why?
|
| Attitude to Health | 7 | 2019 | 218 | 1.060 |
Why?
|
| Motivation | 5 | 2021 | 287 | 1.000 |
Why?
|
| Electronic Health Records | 4 | 2018 | 320 | 0.980 |
Why?
|
| Cancer Survivors | 3 | 2021 | 85 | 0.980 |
Why?
|
| Health Services Needs and Demand | 3 | 2023 | 101 | 0.970 |
Why?
|
| HIV Infections | 4 | 2021 | 773 | 0.950 |
Why?
|
| Papillomaviridae | 11 | 2023 | 153 | 0.930 |
Why?
|
| Young Adult | 25 | 2023 | 5961 | 0.900 |
Why?
|
| Information Seeking Behavior | 2 | 2013 | 12 | 0.880 |
Why?
|
| Health Promotion | 5 | 2019 | 149 | 0.850 |
Why?
|
| Anniversaries and Special Events | 1 | 2022 | 14 | 0.840 |
Why?
|
| Occult Blood | 6 | 2018 | 16 | 0.830 |
Why?
|
| Patient Education as Topic | 4 | 2018 | 342 | 0.820 |
Why?
|
| Health Equity | 1 | 2023 | 77 | 0.820 |
Why?
|
| Persuasive Communication | 2 | 2021 | 7 | 0.790 |
Why?
|
| Head and Neck Neoplasms | 3 | 2023 | 1052 | 0.780 |
Why?
|
| Registries | 8 | 2015 | 701 | 0.760 |
Why?
|
| United States | 31 | 2023 | 6580 | 0.740 |
Why?
|
| Intimate Partner Violence | 1 | 2020 | 20 | 0.740 |
Why?
|
| Male | 49 | 2023 | 40652 | 0.730 |
Why?
|
| Urban Population | 4 | 2022 | 214 | 0.700 |
Why?
|
| Cross-Sectional Studies | 10 | 2023 | 1604 | 0.700 |
Why?
|
| Gonorrhea | 1 | 2019 | 18 | 0.700 |
Why?
|
| Data Accuracy | 2 | 2018 | 31 | 0.690 |
Why?
|
| Chlamydia Infections | 1 | 2019 | 25 | 0.690 |
Why?
|
| Self-Examination | 1 | 2018 | 4 | 0.680 |
Why?
|
| Syphilis | 1 | 2019 | 27 | 0.670 |
Why?
|
| Guideline Adherence | 4 | 2018 | 221 | 0.670 |
Why?
|
| Survivors | 3 | 2015 | 227 | 0.650 |
Why?
|
| Postal Service | 6 | 2023 | 17 | 0.640 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 48 | 0.630 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2019 | 91 | 0.620 |
Why?
|
| Self Report | 3 | 2016 | 288 | 0.590 |
Why?
|
| Aged, 80 and over | 17 | 2022 | 6479 | 0.580 |
Why?
|
| Child | 14 | 2023 | 6930 | 0.570 |
Why?
|
| Anus Neoplasms | 3 | 2021 | 30 | 0.570 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 297 | 0.570 |
Why?
|
| Pilot Projects | 5 | 2023 | 832 | 0.570 |
Why?
|
| Communication | 3 | 2023 | 440 | 0.560 |
Why?
|
| Health Education | 2 | 2015 | 99 | 0.530 |
Why?
|
| Immunization Programs | 3 | 2013 | 23 | 0.530 |
Why?
|
| Public Health Surveillance | 1 | 2015 | 21 | 0.510 |
Why?
|
| Psychological Theory | 2 | 2015 | 22 | 0.510 |
Why?
|
| Health Literacy | 1 | 2016 | 69 | 0.500 |
Why?
|
| Reproducibility of Results | 13 | 2021 | 2702 | 0.490 |
Why?
|
| Veterans | 4 | 2008 | 72 | 0.470 |
Why?
|
| Interviews as Topic | 5 | 2021 | 318 | 0.460 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2023 | 27 | 0.440 |
Why?
|
| Pregnancy in Adolescence | 2 | 2023 | 25 | 0.440 |
Why?
|
| Colonoscopy | 4 | 2017 | 267 | 0.440 |
Why?
|
| Qualitative Research | 4 | 2017 | 256 | 0.430 |
Why?
|
| Risk Factors | 14 | 2023 | 5249 | 0.430 |
Why?
|
| Prevalence | 5 | 2023 | 1210 | 0.410 |
Why?
|
| Mothers | 1 | 2012 | 142 | 0.400 |
Why?
|
| Medically Uninsured | 3 | 2022 | 58 | 0.400 |
Why?
|
| Pandemics | 5 | 2023 | 737 | 0.390 |
Why?
|
| Intention | 3 | 2019 | 51 | 0.390 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 610 | 0.380 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 103 | 0.380 |
Why?
|
| Socioeconomic Factors | 8 | 2018 | 561 | 0.370 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2013 | 8 | 0.370 |
Why?
|
| Social Class | 3 | 2023 | 128 | 0.360 |
Why?
|
| Feasibility Studies | 3 | 2023 | 751 | 0.340 |
Why?
|
| Social Media | 2 | 2023 | 79 | 0.340 |
Why?
|
| Quality of Life | 4 | 2023 | 1581 | 0.330 |
Why?
|
| Colposcopy | 3 | 2023 | 14 | 0.330 |
Why?
|
| Healthcare Disparities | 4 | 2023 | 372 | 0.330 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 57 | 0.330 |
Why?
|
| Patient Selection | 5 | 2021 | 675 | 0.330 |
Why?
|
| Poverty | 5 | 2022 | 173 | 0.320 |
Why?
|
| Rural Population | 2 | 2018 | 136 | 0.300 |
Why?
|
| Primary Health Care | 3 | 2017 | 330 | 0.290 |
Why?
|
| Patient Navigation | 2 | 2016 | 12 | 0.290 |
Why?
|
| Patient Compliance | 3 | 2021 | 220 | 0.290 |
Why?
|
| Residence Characteristics | 4 | 2016 | 193 | 0.280 |
Why?
|
| Health Services Accessibility | 6 | 2021 | 393 | 0.280 |
Why?
|
| Cost-Benefit Analysis | 4 | 2023 | 451 | 0.270 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 468 | 0.260 |
Why?
|
| Retrospective Studies | 10 | 2020 | 8456 | 0.260 |
Why?
|
| Health Care Surveys | 6 | 2013 | 278 | 0.250 |
Why?
|
| Anxiety | 3 | 2023 | 286 | 0.250 |
Why?
|
| Chi-Square Distribution | 4 | 2012 | 358 | 0.250 |
Why?
|
| Caregivers | 2 | 2023 | 151 | 0.250 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 3591 | 0.250 |
Why?
|
| Precision Medicine | 2 | 2020 | 392 | 0.240 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2022 | 70 | 0.240 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 1121 | 0.240 |
Why?
|
| Research | 2 | 2018 | 251 | 0.240 |
Why?
|
| Minority Groups | 3 | 2016 | 137 | 0.240 |
Why?
|
| Community-Institutional Relations | 1 | 2023 | 29 | 0.230 |
Why?
|
| Asthma | 2 | 2022 | 955 | 0.230 |
Why?
|
| Ultrasonography | 4 | 2021 | 692 | 0.230 |
Why?
|
| Pregnancy | 6 | 2023 | 2899 | 0.230 |
Why?
|
| Personal Autonomy | 2 | 2016 | 112 | 0.230 |
Why?
|
| Research Design | 7 | 2020 | 580 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 1137 | 0.220 |
Why?
|
| Intrauterine Devices | 1 | 2023 | 28 | 0.220 |
Why?
|
| Contraceptive Agents, Female | 1 | 2023 | 31 | 0.220 |
Why?
|
| Depression | 3 | 2022 | 472 | 0.220 |
Why?
|
| Cohort Studies | 7 | 2020 | 2738 | 0.210 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 108 | 0.210 |
Why?
|
| California | 5 | 2017 | 137 | 0.210 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2022 | 3 | 0.210 |
Why?
|
| Meningococcal Vaccines | 1 | 2022 | 3 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 5 | 2018 | 992 | 0.210 |
Why?
|
| Adolescent Behavior | 1 | 2023 | 106 | 0.210 |
Why?
|
| Vaccines | 1 | 2023 | 80 | 0.200 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2021 | 8 | 0.200 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1015 | 0.200 |
Why?
|
| Gynecology | 1 | 2023 | 125 | 0.200 |
Why?
|
| Social Sciences | 1 | 2020 | 5 | 0.190 |
Why?
|
| Behavioral Sciences | 1 | 2020 | 3 | 0.190 |
Why?
|
| Behavioral Research | 1 | 2020 | 10 | 0.190 |
Why?
|
| Prospective Studies | 4 | 2023 | 4160 | 0.190 |
Why?
|
| Risk Assessment | 7 | 2021 | 2213 | 0.190 |
Why?
|
| Self Care | 2 | 2022 | 162 | 0.190 |
Why?
|
| Perception | 2 | 2019 | 168 | 0.190 |
Why?
|
| Depressive Disorder, Major | 1 | 2022 | 158 | 0.190 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 149 | 0.190 |
Why?
|
| Reminder Systems | 3 | 2016 | 16 | 0.190 |
Why?
|
| Educational Status | 4 | 2023 | 190 | 0.190 |
Why?
|
| Vulnerable Populations | 2 | 2020 | 76 | 0.190 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2023 | 137 | 0.180 |
Why?
|
| DNA, Viral | 1 | 2020 | 265 | 0.180 |
Why?
|
| Insurance, Health | 4 | 2018 | 156 | 0.180 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2019 | 39 | 0.180 |
Why?
|
| Hospice Care | 2 | 2019 | 39 | 0.180 |
Why?
|
| Uterine Neoplasms | 1 | 2023 | 227 | 0.180 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2019 | 5 | 0.180 |
Why?
|
| Factor Analysis, Statistical | 3 | 2019 | 112 | 0.180 |
Why?
|
| Advance Directives | 2 | 2019 | 64 | 0.180 |
Why?
|
| Precancerous Conditions | 1 | 2021 | 196 | 0.180 |
Why?
|
| Exercise | 2 | 2013 | 309 | 0.170 |
Why?
|
| alpha-Fetoproteins | 2 | 2016 | 45 | 0.170 |
Why?
|
| Urban Health | 1 | 2019 | 54 | 0.170 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 299 | 0.170 |
Why?
|
| Program Evaluation | 2 | 2017 | 290 | 0.170 |
Why?
|
| Advance Care Planning | 1 | 2019 | 43 | 0.170 |
Why?
|
| Decision Making | 2 | 2018 | 643 | 0.160 |
Why?
|
| Research Support as Topic | 2 | 2015 | 80 | 0.160 |
Why?
|
| Vaccination Refusal | 1 | 2018 | 10 | 0.160 |
Why?
|
| Age Factors | 5 | 2018 | 1828 | 0.160 |
Why?
|
| Sex Characteristics | 1 | 2020 | 318 | 0.160 |
Why?
|
| Contraception | 3 | 2023 | 88 | 0.150 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2019 | 487 | 0.150 |
Why?
|
| Palliative Care | 2 | 2019 | 257 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 375 | 0.150 |
Why?
|
| Washington | 1 | 2017 | 48 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 394 | 0.150 |
Why?
|
| Medical Oncology | 1 | 2021 | 360 | 0.150 |
Why?
|
| DNA | 1 | 2023 | 1294 | 0.150 |
Why?
|
| Health Services Research | 2 | 2014 | 136 | 0.150 |
Why?
|
| Rural Health Services | 1 | 2016 | 13 | 0.150 |
Why?
|
| Medically Underserved Area | 1 | 2016 | 25 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 160 | 0.140 |
Why?
|
| Discriminant Analysis | 1 | 2016 | 66 | 0.140 |
Why?
|
| Hormones | 1 | 2017 | 140 | 0.140 |
Why?
|
| Nitriles | 1 | 2017 | 148 | 0.140 |
Why?
|
| Ultrasonography, Doppler | 1 | 2016 | 80 | 0.140 |
Why?
|
| Tape Recording | 1 | 2016 | 19 | 0.140 |
Why?
|
| Triazoles | 1 | 2017 | 96 | 0.140 |
Why?
|
| Literacy | 1 | 2016 | 2 | 0.140 |
Why?
|
| Medicaid | 2 | 2017 | 217 | 0.140 |
Why?
|
| Attitude of Health Personnel | 3 | 2023 | 632 | 0.140 |
Why?
|
| Regression Analysis | 3 | 2017 | 593 | 0.140 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 44 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 150 | 0.140 |
Why?
|
| Tamoxifen | 1 | 2017 | 168 | 0.140 |
Why?
|
| Attitude to Death | 1 | 2016 | 36 | 0.140 |
Why?
|
| Hospitals, Community | 1 | 2015 | 32 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2017 | 180 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2017 | 123 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 484 | 0.130 |
Why?
|
| Hospitals, University | 1 | 2015 | 194 | 0.130 |
Why?
|
| Adenoma | 1 | 2017 | 236 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 1168 | 0.130 |
Why?
|
| Community-Based Participatory Research | 1 | 2014 | 35 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1200 | 0.120 |
Why?
|
| Specimen Handling | 3 | 2020 | 98 | 0.120 |
Why?
|
| Terminal Care | 1 | 2016 | 130 | 0.120 |
Why?
|
| Biomarkers | 1 | 2020 | 1697 | 0.120 |
Why?
|
| Time Factors | 3 | 2018 | 5178 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2018 | 426 | 0.120 |
Why?
|
| Psychometrics | 3 | 2019 | 327 | 0.120 |
Why?
|
| ROC Curve | 1 | 2016 | 752 | 0.120 |
Why?
|
| Physicians | 1 | 2021 | 672 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 744 | 0.110 |
Why?
|
| Sexual Behavior | 2 | 2023 | 302 | 0.110 |
Why?
|
| Nuclear Family | 2 | 2023 | 92 | 0.110 |
Why?
|
| Contraceptive Agents | 2 | 2023 | 20 | 0.110 |
Why?
|
| Genetic Counseling | 1 | 2013 | 100 | 0.110 |
Why?
|
| Infant | 1 | 2019 | 3049 | 0.110 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 2261 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2019 | 3612 | 0.110 |
Why?
|
| Gammapapillomavirus | 1 | 2011 | 1 | 0.100 |
Why?
|
| Health Personnel | 2 | 2018 | 201 | 0.100 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2011 | 6 | 0.100 |
Why?
|
| Beneficence | 1 | 2011 | 33 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1465 | 0.100 |
Why?
|
| Social Behavior | 1 | 2014 | 295 | 0.100 |
Why?
|
| Family Characteristics | 1 | 2011 | 48 | 0.100 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2011 | 45 | 0.100 |
Why?
|
| Confidentiality | 1 | 2011 | 77 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2015 | 574 | 0.100 |
Why?
|
| Research Personnel | 1 | 2011 | 67 | 0.100 |
Why?
|
| Data Collection | 2 | 2013 | 372 | 0.100 |
Why?
|
| Sex Factors | 2 | 2012 | 1041 | 0.100 |
Why?
|
| Immunization | 1 | 2011 | 159 | 0.100 |
Why?
|
| Logistic Models | 3 | 2013 | 1179 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 836 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 378 | 0.090 |
Why?
|
| Cognition | 1 | 2014 | 570 | 0.090 |
Why?
|
| Anxiety Disorders | 2 | 2021 | 146 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2013 | 533 | 0.090 |
Why?
|
| Informed Consent | 1 | 2011 | 266 | 0.080 |
Why?
|
| Choice Behavior | 1 | 2010 | 160 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2017 | 676 | 0.080 |
Why?
|
| Incidence | 3 | 2020 | 1543 | 0.080 |
Why?
|
| Income | 1 | 2008 | 76 | 0.080 |
Why?
|
| Sigmoidoscopy | 1 | 2008 | 36 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2013 | 756 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1938 | 0.080 |
Why?
|
| Hysterectomy | 1 | 2008 | 146 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2008 | 901 | 0.070 |
Why?
|
| Patient Participation | 2 | 2021 | 215 | 0.070 |
Why?
|
| Social Marketing | 1 | 2006 | 10 | 0.070 |
Why?
|
| Pamphlets | 1 | 2006 | 14 | 0.070 |
Why?
|
| Health Status | 1 | 2008 | 360 | 0.070 |
Why?
|
| Focus Groups | 2 | 2017 | 155 | 0.070 |
Why?
|
| Self Disclosure | 1 | 2006 | 31 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2360 | 0.070 |
Why?
|
| Prognosis | 3 | 2020 | 3639 | 0.070 |
Why?
|
| Insurance Coverage | 2 | 2016 | 117 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 61 | 0.070 |
Why?
|
| Demography | 1 | 2005 | 177 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2005 | 159 | 0.060 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2023 | 12 | 0.060 |
Why?
|
| Telephone | 2 | 2016 | 32 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 1655 | 0.060 |
Why?
|
| Philadelphia | 1 | 2022 | 16 | 0.060 |
Why?
|
| Likelihood Functions | 2 | 2019 | 251 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2022 | 136 | 0.050 |
Why?
|
| Immunization Schedule | 1 | 2022 | 21 | 0.050 |
Why?
|
| Travel | 1 | 2022 | 68 | 0.050 |
Why?
|
| Child Abuse, Sexual | 1 | 2002 | 19 | 0.050 |
Why?
|
| Bias | 1 | 2022 | 127 | 0.050 |
Why?
|
| Life Change Events | 1 | 2002 | 48 | 0.050 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2021 | 2 | 0.050 |
Why?
|
| Complementarity Determining Regions | 1 | 2021 | 24 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2021 | 38 | 0.050 |
Why?
|
| Child Abuse | 1 | 2002 | 78 | 0.050 |
Why?
|
| Conflict of Interest | 1 | 2021 | 67 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 38 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 19 | 0.050 |
Why?
|
| Mass Vaccination | 1 | 2020 | 8 | 0.050 |
Why?
|
| Suicide, Attempted | 1 | 2002 | 129 | 0.050 |
Why?
|
| Spain | 1 | 2020 | 33 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2020 | 7830 | 0.050 |
Why?
|
| Population Health | 1 | 2020 | 33 | 0.050 |
Why?
|
| Mental Health | 1 | 2021 | 162 | 0.050 |
Why?
|
| Ethics, Research | 1 | 2020 | 52 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2004 | 374 | 0.050 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2019 | 5 | 0.050 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2020 | 45 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2020 | 159 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 985 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 309 | 0.040 |
Why?
|
| Living Wills | 1 | 2019 | 4 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 147 | 0.040 |
Why?
|
| Developing Countries | 1 | 2020 | 71 | 0.040 |
Why?
|
| Medicare | 1 | 2023 | 408 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 129 | 0.040 |
Why?
|
| Patient Preference | 1 | 2020 | 104 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 164 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 304 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 123 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 232 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2018 | 65 | 0.040 |
Why?
|
| Ovary | 1 | 2020 | 258 | 0.040 |
Why?
|
| Professional Practice Gaps | 1 | 2018 | 1 | 0.040 |
Why?
|
| Vaccination Coverage | 1 | 2018 | 5 | 0.040 |
Why?
|
| Information Systems | 1 | 2018 | 29 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2022 | 1989 | 0.040 |
Why?
|
| Health Surveys | 2 | 2008 | 236 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 456 | 0.040 |
Why?
|
| Intestinal Polyps | 1 | 2017 | 26 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 148 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2018 | 112 | 0.040 |
Why?
|
| Interinstitutional Relations | 1 | 2016 | 28 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2016 | 93 | 0.040 |
Why?
|
| Motivational Interviewing | 1 | 2016 | 18 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 580 | 0.040 |
Why?
|
| Osteocalcin | 1 | 1996 | 26 | 0.040 |
Why?
|
| Feces | 1 | 2018 | 320 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 156 | 0.030 |
Why?
|
| Osteoblasts | 1 | 1996 | 96 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2016 | 153 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1388 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2015 | 78 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1163 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1696 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 428 | 0.030 |
Why?
|
| Personnel Selection | 1 | 2014 | 59 | 0.030 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Small-Area Analysis | 1 | 2013 | 8 | 0.030 |
Why?
|
| Multilevel Analysis | 1 | 2013 | 21 | 0.030 |
Why?
|
| Communication Barriers | 1 | 2012 | 29 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2015 | 170 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 1996 | 538 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2013 | 234 | 0.030 |
Why?
|
| Hepatitis C, Chronic | 1 | 2013 | 126 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 1137 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1760 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 1018 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 1849 | 0.020 |
Why?
|
| Publication Bias | 1 | 2010 | 13 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 364 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 226 | 0.020 |
Why?
|
| Medicine | 1 | 2010 | 90 | 0.020 |
Why?
|
| Counseling | 1 | 2010 | 145 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2013 | 512 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2008 | 53 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 415 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 812 | 0.020 |
Why?
|
| Georgia | 1 | 2002 | 34 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1996 | 68 | 0.010 |
Why?
|
| Nucleotides | 1 | 1996 | 95 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1996 | 205 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1996 | 498 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1996 | 1041 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1996 | 716 | 0.010 |
Why?
|
| Binding Sites | 1 | 1996 | 1104 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1996 | 943 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1996 | 1471 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 3997 | 0.010 |
Why?
|
| Mutation | 1 | 1996 | 3978 | 0.000 |
Why?
|
| Animals | 1 | 1996 | 26650 | 0.000 |
Why?
|